PMCB
PharmaCyte Biotech, Inc.
Healthcare — Biotechnology
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Price History
Fundamentals
| Market Cap | $7.96M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.95 |
| EPS (TTM) | $-0.89 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -8.24% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 54.7 |
| Beta | 0.52 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $1.51 |
| 52-Week Low | $0.63 |
| 50-Day Avg | $0.77 |
| 200-Day Avg | $0.82 |
| Avg Volume | 182.3K |
| Volume | 60.1K |
Performance Analysis
NEUTRALPMCB presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:26 UTC
Back to Screener Export Report